# Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery

> **NCT00242502** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 62 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Liver Cancer

## Interventions

- **DRUG:** Bevacizumab (Avastin)
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00242502
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2013-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00242502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00242502, "Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00242502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*